Posttherapeutic cure criteria in chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1283-1291

  Machado de Assis, G F ^a   Silva, A R ^a   Do Bem, V A L ^a   Bahia, M T ^a   Martins Filho, O A ^b   Dias, J C P ^b   Albajar Vinas P ^c   Torres, R M ^d   Lana, M ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Organização Mundial da Saúde   (Switzerland)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CHAGAS DISEASE; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION TEST; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARASITE IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; SYNDROME DELINEATION; TRYPANOSOMA CRUZI;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NITROIMIDAZOLES; PARASITOLOGY; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 84864544656     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00274-12     Document Type: Article

References (55)

1. Andrade SG, Freitas LAR, Peyrol S, Pimentel AR, Sadigursky M. 1991. Experimental chemotherapy of Trypanosoma cruzi reveals infection persistence of parasite antigens and positive serology in parasitologically cured mice. Bull. World Health Organ. 69:191-199.
2. Ávila HA, et al. 1993. Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J. Clin. Microbiol. 31:2421-2426. (Pubitemid 23254212)
3. Britto CC, et al. 2001. Parasite persistence in treated chagasic patients revealed by xenodiagnostic and polymerase chain reaction. Mem. Inst. Oswaldo Cruz 96:823-826.
4. Caballero ZC, Sousa OE, Marques WP, Saes-Alquezar A, Umezawa E. 2007. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin. Vaccine Immunol. 14:1045-1049.
5. Cançado JR. 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44:29-37. (Pubitemid 34205107)
6. Castro AM, et al. 2002. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol. Res. 88:894-900.
7. Chiari E, Dias JCP, Lana M, Chiari CA. 1989. Hemocultures for the parasitological diagnosis of human chronic Chagas' disease. Rev. Soc. Bras. Med. Trop. 22:19-23. (Pubitemid 20268273)
8. Coura JR, Castro SL. 2002. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97:3-24. (Pubitemid 135746197)
9. de Andrade AL, et al. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413.
10. Dias JCP, Machado EMM, Fernandes AL, Vinhães MC. 2000. Esboço geral e perspectivas da doença de Chagas no Nordeste do Brasil. Cad. Saude Publica 16(Suppl. II):13-34.
11. Escribà JM, et al. 2009. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem. Inst. Oswaldo Cruz 104:986-991.
12. Fernandes CD, et al. 2009. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem. Inst. Oswaldo Cruz 104:27-32.
13. Ferreira AW, Belem ZR, Lemos EA, Reed SG, Campo-Neto A. 2001. Enzyme-linked immunosorbent assay for serological diagnosis of Chagas disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J. Clin. Microbiol. 39:4390-4395. (Pubitemid 33117128)
14. Furuchó CR, et al. 2008. Inconclusive results in conventional serological screening for Chagas disease in blood banks: evaluation of cellular and humoral response. Trop. Med. Int. Health. 13:1527-1533.
15. Galvão LMC, Nunes RMB, Cançado JR, Brener Z, Krettli AU. 1993. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 87:220-223.
16. Galvão LMC, et al. 2003. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J. Clin. Microbiol. 41:5066-5070.
17. Gazzinelli RT, et al. 1993. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Am. J. Trop. Med. Hyg. 49:625-635.
18. Gomes ML, et al. 1998. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Exp. Parasitol. 88:28-33. (Pubitemid 28375811)
19. Gomes ML, Galvão LM, Macedo AM, Pena SD, Chiari E. 1999. Chagas disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am. J. Trop. Med. Hyg. 60:205-210.
20. Krautz GM, Coutinho MG, Galvão LM, Cançado JR, Krettli AU. 1994. Antígenos solúveis liberados por tripomastigotas de Trypanosoma cruzi utilizados no teste de ELISA para detectar cura em pacientes chagásicos após tratamento específico. Rev. Soc. Bras. Med. Trop. 27:199-207.
21. Krautz GM, et al. 1995. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J. Clin. Microbiol. 33:2086-2090.
22. Krettli AU, Cançado JR, Brener Z. 1984. Criterion of cure of human Chagas disease after specific chemotherapy, recent advances. Mem. Inst. Oswaldo Cruz 79:157-164.
23. Krettli AU. 2009. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem. Inst. Oswaldo Cruz 104(Suppl. I):142-151.
24. Lana M, et al. 2009. Clinical and laboratorial status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Mem. Inst. Oswaldo Cruz 104(8):1139-1147.
25. Lauria-Pires L, et al. 2000. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am. J. Trop. Med. Hyg. 63:111-118. (Pubitemid 32488345)
26. Luquetti A. 1997. The National Health Foundation of Brazil, etiological treatment for Chagas disease. Parasitol. Today 13:127-128.
27. Luquetti AO, Rassi A. 2002. Perspectiva del uso de la serologia (Ag naturales y otros) en la evaluación de la eficácia del tratamiento etiológico. Conferência 2002. http://www.fac.org.ar/fec/chagas2/ llave/c003/luque.htm. (Updated 22 December 2010.)
28. Luz ZMP, Coutinho MC, Cançado JR, Krettli AU. 1994. Hemocultura: técnica sensível na detecção do Trypanosoma cruzi em pacientes chagásicos na fase crônica da doença de Chagas. Rev. Soc. Bras. Med. Trop. 27:143-148.
29. Marcon GEB, et al. 2002. Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. Diagn. Microbiol. Infect. Dis. 43:39-43. (Pubitemid 34607515)
30. Marin-Neto JA, et al. 2009. The BENEFIT Trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz 104(Suppl. I):319-324.
31. Martins-Filho OA, Pereira MES, Carvalho JAC, Cançado JR, Brener Z. 1995. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas'disease. Clin. Diagn. Lab. Immunol. 2:569-573.
32. Martins-Filho OA, et al. 2002. Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clin. Diagn. Lab. Immunol. 9:1107-1113. (Pubitemid 34988483)
33. Meira WSF, et al. 2004. Use of Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J. Clin. Microbiol. 42:707-712. (Pubitemid 38222650)
34. Ministério da Saúde. Secretaria de Vigilância em Saúde. 2005. Brasilian consensus on Chagas disease. Rev. Soc. Bras. Med. Trop. 38(Suppl 3):7-29. (In Portuguese.)
35. Prata A. 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1:92-100. (Pubitemid 33586044)
36. Rezende JM, Lauar KL, Oliveira AR. 1960. Aspectos clínicos e radiológicos da aperistalsis do esôfago. Rev. Bras. Gastroenterol. 12:247-262.
37. Russomando G, et al. 1998. Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. Am. J. Trop. Med. Hyg. 59:487-491. (Pubitemid 28429096)
38. Sánchez Negrette OS, et al. 2008. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clin. Vaccine Immunol. 15:297-302.
39. Santos LS, et al. 2012. In-house ELISA method to analyze anti-Trypanosoma cruzi IgG reactivity for differential diagnosis and evaluation of Chagas disease morbidity. Rev. Soc. Bras. Med. Trop. 45(1):35-44.
40. Schijman AG, et al. 2003. Aetiological treatment of congenital Chagas'disease diagnosed and monitored by the polymerase chain reaction. J. Antimicrob. Chemother. 52:441-449. (Pubitemid 37120724)
41. Schijman AG, et al. 2011. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl. Trop. Dis. 5(1):e931. doi:10.1371/journal.pntd.0000931.
42. Silva ED, et al. 2002. Use of the EIE-recombinant-Chagas-Biomanguinhos kit to monitor cure of human Chagas' disease. J. Clin. Lab. Anal. 16:132-136. (Pubitemid 34492364)
43. Silveira-Lacerda EP, et al. 2004. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang. 87:204-207. (Pubitemid 39469780)
44. Tarleton RL, Zhang L. 1999. Chagas' disease etiology: autoimmunity or parasite persistence? Parasitol. Today 15:94-99.
45. Umezawa ES, et al. 1996. Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease. J. Clin. Microbiol. 34:2143-2147. (Pubitemid 26272193)
46. Umezawa ES, et al. 1999. Evaluation of recombinant antigens for sero-diagnosis of Chagas' disease in South and Central America. J. Clin. Microbiol. 37:1554-1560. (Pubitemid 29187833)
47. Umezawa ES, Nascimento MS, Stolf AMS. 2001. Enzyme-linked immunosorbent assay with Trypanosoma cruzi excreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas disease. Diagn. Microbiol. Infect. Dis. 39:169-176. (Pubitemid 32406173)
48. Umezawa ES, et al. 2003. An improved serodiagnostic test for Chagas disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion 43:91-97. (Pubitemid 36322902)
49. Viotti R, Vigliano C, Armenti H, Segura E. 1994. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 127:151-162. (Pubitemid 24040442)
50. Viotti R, et al. 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144:724-734. (Pubitemid 46780632)
51. Voller A, Draper C, Bidwell DE, Bartlett AA. 1975. Microplate enzyme-linked immunosorbent assay (ELISA) for Chagas disease. Lancet 305: 426-428.
52. WHO Expert Committee on the Control of Chagas Disease. 2002. Control of Chagas disease. Second report of the WHO expert committee. World Health Organ. Tech. Rep. Ser. 905:1-109.
53. World Health Organization. 2010. First WHO report on neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases. http://www.who.int/neglected-diseases/2010report/en/.
54. Yun O, et al. 2009. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl. Trop. Dis. 3(7):e488. doi:10.1371/journal.pntd.0000488.
55. Zarate-Blades CR, Bladés N, Nascimento MS, da Silveira JF, Umezawa ES. 2007. Diagnostic performance of tests based on Trypanosoma cruzi excreted-secreted antigens in an endemic area for Chagas disease in Bolivia. Diagn. Microbiol. Infect. Dis. 57:229-232. (Pubitemid 46135870)